Psychedelics for major depression-From controlled research settings into broader clinical use.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40961925.
- Also identified by DOI 10.1016/j.xcrm.2025.102361 and PMC identifier 12490253.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Psychedelics have shown promising antidepressant effects in recent phase 2 randomized controlled trials, with phase 3 studies underway. While therapeutic outcomes are encouraging, the underlying mechanisms-from receptor-level pharmacology to subjective experience and context-remain only partially understood. We highlight clinical and mechanistic advances and outline priorities for future research.
Medical subject headings
- Major Depressive Disorder
- Hallucinogens
- Antidepressive Agents